Gibco™ HAT Supplement is a liquid mixture of sodium hypoxanthine (5 mM), aminopterin (20 μM) and thymidine (0.8 mM). HAT-supplemented medium is suitable for post-fusion selection against unfused or self-fused HGPRT–myeloma cells. Hypoxanthine and thymidine supply preformed purines and pyrimidines for DNA synthesis by hybridomas via the salvage pathway that utilizes HGPRT- contributed by the fused spleen cell. Aminopterin, a folic acid antagonist, inhibits the de novo nucleoside biosynthesis pathway.

Product Use
For Research Use Only. Not for use in diagnostic procedures.

Dual site cGMP Manufacturing and Quality System
For supply chain continuity, we manufacture Gibco™ HAT Supplement at two separate facilities located in Grand Island, NY and Scotland, UK. Both sites are compliant with cGMP manufacturing requirements, are certified to ISO 13485, and are registered with the FDA as medical device manufacturers.